10-Q · May 6, 2026
Revolution Medicines reported disappointing financial results for Q1 2026, with no revenue and an EPS loss of -2.29, missing consensus estimates of -1.84. The company incurred significant operational expenses, including…
Earnings analysis · 10-Q
RVMD earnings analysis
Filed November 4, 2026 · Our reading of the company's report
The latest report
Revolution Medicines reported $197.6 million of revenue and $(1.90) diluted EPS following the August 2026 RASONQUE launch, materially exceeding consensus estimates of $27.6 million and $(2.37), respectively. Liquidity…
Read full summary
Revolution Medicines reported $197.6 million of revenue and $(1.90) diluted EPS following the August 2026 RASONQUE launch, materially exceeding consensus estimates of $27.6 million and $(2.37), respectively. Liquidity was strong at $3.7 billion, supported by $352.6 million of ATM proceeds, but the company remains deeply loss-making with a $4.4 billion accumulated deficit and added $250.0 million of secured debt after quarter-end. Management maintained 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion, while launch-channel variability, safety, manufacturing execution and increasing leverage remain material risks.
Reported figures
- Earnings per share
- $-1.9
- Segment
- RASONQUE: $197.6 million of revenue; no other reportable segment revenue disclosed
What stood out
-
RASONQUE launch drove major revenue beat
Revenue was $197.6 million and diluted EPS was $(1.90), reflecting the partial-quarter commercial launch of RASONQUE in August 2026. Revenue substantially exceeded the $27.6 million consensus estimate, while EPS exceeded the $(2.37) estimate.
-
Liquidity expanded materially
Cash, cash equivalents and marketable securities increased to $3.7 billion at September 30, 2026 from $2.0 billion at December 31, 2025, an increase of approximately $1.7 billion.
-
ATM financing added $352.6 million
The company sold 2,950,997 common shares under its ATM programs during the nine months ended September 30, 2026, generating net proceeds of $352.6 million.
-
Additional debt financing available
Following FDA approval, the company drew the first $250.0 million tranche under its Term Loan Facility in October 2026, and may have access to up to an additional $500.0 million under the loan agreement subject to conditions.
-
European regulatory progress
The CHMP adopted a positive opinion in October 2026 recommending EU marketing authorization for RASONQUE in previously treated metastatic pancreatic adenocarcinoma, expanding potential commercial reach beyond the U.S.
-
Launch-related controls implemented
Management concluded that disclosure controls and procedures were effective as of September 30, 2026, while implementing new revenue, order-to-cash, inventory and receivables controls associated with the commercial launch.
What to watch
-
Large losses and uncertain profitability
The company had an accumulated deficit of $4.4 billion as of September 30, 2026 and stated that it expects to incur losses for at least the next several years, despite generating $197.6 million of quarterly revenue.
-
Leverage and secured obligations increased
As of September 30, 2026, the company had $500.0 million of 2033 Notes, approximately $572.3 million of royalty-sale liabilities and, after quarter-end, $250.0 million of secured term loans. The term-loan collateral includes substantially all assets, including intellectual property.
-
Floating-rate interest exposure
Borrowings under the Term Loan Facility bear interest at three-month term SOFR plus 5.75%, subject to a 3.5% floor; a 100-basis-point increase in SOFR would increase annual interest expense by approximately $2.5 million on $250.0 million of borrowings.
-
Launch revenue may not be repeatable
Initial launch revenue may be volatile because reported product revenue can be affected by distributor inventory levels, rebates, chargebacks, discounts, returns and other deductions; the company specifically identifies demand and channel inventory as sources of significant fluctuation.
-
Commercial safety and tolerability risk
RASONQUE carries warnings and precautions for dermatologic and soft tissue toxicity, stomatitis and oral disorders, diarrhea, gastrointestinal perforation, interstitial lung disease or pneumonitis, and embryo-fetal toxicity; adverse events could lead to label restrictions or reduced adoption.
-
Manufacturing and supply-chain concentration
The company relies on third parties for commercial supply of RASONQUE and some suppliers are sole sources. If a supplier were designated a biotechnology company of concern, the company could be required to qualify alternatives, potentially interrupting supply to patients.
Management's outlook
Management maintained full-year 2026 GAAP operating expense guidance of $2.1 billion to $2.2 billion, including $270 million to $290 million of stock-based compensation expense. No quantitative revenue or EPS guidance was provided in the supplied 10-Q text.
Earlier filings 1
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.